Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

2.670 -0.040 (-1.48%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,109,000
Open	2.870
Bid (Size)	2.650 (100)
Ask (Size)	2.690 (2,300)
Prev. Close	2.710
Today's Range	2.605 - 2.870
52wk Range	1.195 - 4.940
Shares Outstanding	36,213,654
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

December 03, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

December 02, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Performance

YTD	+24.8%	+24.8%
1 Month	-31.0%	-31.0%
3 Month	-9.2%	-9.2%
6 Month	+3.5%	+3.5%
1 Year	+13.6%	+13.6%

More News

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

November 06, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 06, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗

October 10, 2025

Via Benzinga

Black Diamond (BDTX) Q2 Loss Narrows 47% ↗

August 07, 2025

Via The Motley Fool

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 07, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 29, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

March 31, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

These stocks have an unusual volume in today's session ↗

March 21, 2025

Via Chartmill

Unusual volume stocks in Thursday's session ↗

March 20, 2025

Via Chartmill

These stocks are the most active in today's session ↗

March 19, 2025

Via Chartmill

What's going on in today's session ↗

March 19, 2025

Via Chartmill

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High ↗

March 19, 2025

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 19, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

March 19, 2025

Via Chartmill

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million ↗

March 19, 2025

Via Benzinga

Discover the top movers in Wednesday's pre-market session. ↗

March 19, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 19, 2025

Via Benzinga

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

March 19, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 06, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗

January 13, 2025

Via Benzinga

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 05, 2024

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

November 01, 2024

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Frequently Asked Questions

Is Black Diamond Therapeutics, Inc. - Common Stock publicly traded?

Yes, Black Diamond Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Black Diamond Therapeutics, Inc. - Common Stock trade on?

Black Diamond Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock?

The ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock is BDTX on the Nasdaq Stock Market

What is the current price of Black Diamond Therapeutics, Inc. - Common Stock?

The current price of Black Diamond Therapeutics, Inc. - Common Stock is 2.670

When was Black Diamond Therapeutics, Inc. - Common Stock last traded?

The last trade of Black Diamond Therapeutics, Inc. - Common Stock was at 12/05/25 04:00 PM ET

What is the market capitalization of Black Diamond Therapeutics, Inc. - Common Stock?

The market capitalization of Black Diamond Therapeutics, Inc. - Common Stock is 96.69M

How many shares of Black Diamond Therapeutics, Inc. - Common Stock are outstanding?

Black Diamond Therapeutics, Inc. - Common Stock has 97M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.